<DOC>
	<DOCNO>NCT03038997</DOCNO>
	<brief_summary>To evaluate cardiac MRI and/or serum biomarkers detect cardiac cardiac toxicity child receive anthracycline base chemotherapy ( ABC ) .</brief_summary>
	<brief_title>Early Detection Cardiac Toxicity Childhood Cancer Survivors</brief_title>
	<detailed_description>Cardiac toxicity significant potential complication patient receive anthracycline chemotherapy . Cells cardiovascular system limit regenerative capability , make susceptible long term adverse effect chemotherapeutic agent . The ability detect subclinical change cardiac function allow clinician use proven treatment prevent progression vulnerable population . The current standard test us echocardiography , sensitive cardiac MRI serum biomarkers .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Subjects receive anthracycline base chemotherapy Age : 8 year old 25 year old Subjects require sedation cardiac MRI . Subjects must complete treatment last 10 year Patients significant congenital heart defect Patients renal injury renal failure , define estimate glomerular filtration rate [ eGFR ] &lt; 30 ml/min/1.73 m2 body surface area ) , previously calculate ) Patients require sedation cardiac MRI Subjects pregnant lactating Patients contraindication cardiac MRI : Cardiac pacemaker implantable defibrillator Cerebral aneurysm clip Neural stimulator Metallic ocular foreign body Any implanted device ( i.e . insulin pump , drug infusion device ) Claustrophobia Metal shrapnel bullet Investigator assessment inability comply protocol Unable/unwilling lie still throughout research procedure Persons cognitive impairment</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>